Affinity Asset Advisors, LLC Xenon Pharmaceuticals Inc. Transaction History
Affinity Asset Advisors, LLC
- $560 Million
- Q4 2024
A detailed history of Affinity Asset Advisors, LLC transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Affinity Asset Advisors, LLC holds 1,161,237 shares of XENE stock, worth $46.1 Million. This represents 8.14% of its overall portfolio holdings.
Number of Shares
1,161,237
Previous 1,144,021
1.5%
Holding current value
$46.1 Million
Previous $45 Million
1.12%
% of portfolio
8.14%
Previous 7.78%
Shares
13 transactions
Others Institutions Holding XENE
# of Institutions
219Shares Held
70.4MCall Options Held
109KPut Options Held
2.1K-
Avoro Capital Advisors LLC New York, NY5.67MShares$225 Million3.24% of portfolio
-
Driehaus Capital Management LLC Chicago, IL4.52MShares$180 Million1.73% of portfolio
-
Wellington Management Group LLP Boston, MA3.78MShares$150 Million0.03% of portfolio
-
Braidwell LP Stamford, CT2.91MShares$116 Million6.4% of portfolio
-
Janus Henderson Group PLC London, X02.87MShares$114 Million0.06% of portfolio
About Xenon Pharmaceuticals Inc.
- Ticker XENE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 62,263,500
- Market Cap $2.47B
- Description
- Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...